myLaminin Perspectives

Five years ago, myLaminin began with a single idea. Today, it has evolved into a connected research ecosystem supporting the complete research lifecycle—from grant submission through publication. Discover how one conversation with a Canadian U15 university transformed our vision, how researchers co-designed our platform, and how myLaminin became a sovereign Research Data Management (RDM) and Clinical Trial Management System (CTMS) built for active science.

The new ICH E6(R3) guidelines are transforming clinical research worldwide, requiring Quality-by-Design, risk-based oversight, and validated digital systems. Discover how myLaminin's co-designed Clinical Trial Operations (CTOps) and CTMS platform helps research teams, principal investigators, administrators, and compliance professionals streamline operations, strengthen data integrity, improve audit readiness, and meet evolving global regulatory requirements with confidence.

Clinical trial start-up delays continue to impact site activation, budgets, and timelines due to fragmented workflows across feasibility, contracting, IRB/REB approvals, training, and system readiness. This article explains how CTMS platforms, integrated research systems, and AI-driven automation reduce inefficiencies by centralizing processes, improving visibility, and accelerating trial activation across global clinical research environments.

ICH E6 (R3) is reshaping clinical trial compliance across Canada, the U.S., EU, UK, and Australia. The updated Good Clinical Practice (GCP) guideline emphasizes Quality by Design, proactive risk management, audit trail traceability, sponsor oversight, informed consent, data integrity, and inspection readiness. myLaminin helps research teams and sponsors manage multi-site clinical trials with real-time oversight, CTQ monitoring, compliant eConsent, secure audit trails, and val

Modern clinical trials demand integrated systems to streamline workflows, centralize data, and ensure compliance. Fragmented tools slow research, increase costs, and risk errors, while platforms like myLaminin CTMS enhance efficiency, oversight, and data quality. By accelerating studies without compromising accuracy, modern clinical trial infrastructure supports faster, safer drug development and more reliable outcomes for patients.

CROs have evolved into essential partners in clinical trials, offering scalability, expertise, and global reach amid rising complexity. However, fragmented systems, blurred oversight, and data silos create risk. The future lies in integrated platforms like myLaminin that connect sponsors, CROs, and sites, improving transparency, governance, and execution across decentralized research ecosystems.

Research Data Management is often treated as overhead but the real cost shows up in lost researcher time, duplicated tools, compliance risk, and missed funding opportunities. This article breaks down the hidden financial impact of poor RDM and explains how universities can calculate real ROI. If budgets are tight and accountability is rising, RDM can no longer be an afterthought, it’s a strategic investment.

Publishing in peer-reviewed journals is more than tradition—it’s a strategic step in advancing careers, meeting funder mandates, and fueling scientific progress. In today’s data-driven world, platforms like myLaminin support researchers at every stage, from managing metadata and version control to ensuring compliance and transparency. With myLaminin, publishing becomes not only easier but also more impactful, aligning with modern research demands.

Robust Research Data Management (RDM) is the backbone of reliable digital twins, ensuring consistent, accurate, and scalable data inputs. Without it, even the best models can mislead. myLaminin, a blockchain-enabled RDM platform, empowers organizations to govern data across systems with integrity and flexibility. With features like immutable audit trails and customizable storage, myLaminin helps digital twin projects stay accurate, compliant, and future-ready.